
Premarket Notification [510(k)] Submissions for Electrosurgical Devices for General Surgery

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only. Document issued on: March 24, 2014

 You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.





U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of Device Evaluation
Division of Surgical Devices
General Surgery Devices Branch 2

Draft - Not for Implementation

35	Preface
36	
37	Additional Copies
38	•
39	Additional copies are available from the Internet. You may also send an e-mail request to
40	<u>CDRH-Guidance@fda.hhs.gov</u> to receive a copy of the guidance. Please use the document
41	number 1835 to identify the guidance you are requesting.
42	
43	



Contains Nonbinding Recommendations Draft - Not for Implementation

44	Table of Contents	
45		
46	I. Introduction	2
47	II. Scope	2
48	III. Device Description	
49	A. Indications for Use	3
50	B. Device Design	4
51	IV. Substantial Equivalence Comparison	5
52	V. Software	6
53	VI. Biocompatibility	7
54	VII. Sterility	9
55	VIII. Reprocessing	9
56	IX. Pyrogenicity	1(
57	X. Shelf Life	1(
58	XI. Performance Data	11
59	A. Electrosurgical Unit	11
60	B. Active Accessory	11
61	C. Neutral Electrodes	12
62	D. Miscellaneous Accessories	12
63	E. System Testing	12
64	XII. Electrical Safety and Electromagnetic Compatibility	13
65	XIII. Clinical Testing	14
66	XIV. Labeling	. 15
67	A. Instructions for Use (User Manual)	16
68	B. Device Labels	18
69	C. Package Labels	18
70	D. Labeling for Specific Components	18
71	Appendix A: Glossary of Terms	20
72 73		

Draft - Not for Implementation

Premarket Notification [510(k)] Submissions for Electrosurgical Devices for General Surgery

Draft Guidance for Industry and Food and Drug Administration Staff

80 81

82

83

84

85

86

87

88

99

100

101

102

74

75

76 77

78

79

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. Introduction

- 89 FDA has developed this guidance document to assist industry in preparing premarket
- 90 notification submissions [510(k)] for electrosurgical devices intended for use in general
- 91 surgery. These devices are designed to cut and/or remove tissue and control bleeding through
- 92 the use of high-frequency electrical current. For the purpose of this guidance, electrosurgical
- 93 devices may also be called radiofrequency (RF) devices or high frequency (HF) devices.
- 94 FDA's guidance documents, including this guidance, do not establish legally enforceable
- 95 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and
- should be viewed only as recommendations, unless specific regulatory or statutory
- 97 requirements are cited. The use of the word *should* in Agency guidances means that
- something is suggested or recommended, but not required.

II. Scope

- The scope of this document is limited to the Class II, electrosurgical devices and accessories classified under the following regulation number:
 - Section 878.4400 Electrosurgical cutting and coagulation device and accessories.
- An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.
- Electrosurgical devices under this regulation are indicated for general tissue cutting and
- 106 coagulation. If your device has specific indications, it may require additional information
- 107 (e.g., clinical data) or may be found to have a new intended use. For more information on this
- topic, please refer to FDA's "Guidance for Industry: General/Specific Intended Use,"

Draft - Not for Implementation

- $109 \qquad (\underline{http://www.fda.gov/downloads/MedicalDevices/DeviceRegulation and Guidance/GuidanceD})$
- 110 <u>ocuments/ucm073945.pdf</u>).
- There are electrosurgical devices that have been classified under other medical panels (e.g.,
- 112 21 CFR 872 for dental). This guidance is not applicable to devices classified under the
- 113 following regulations:
- Section 872.4920 Dental electrosurgical unit and accessories.
- Section 876.4300 Endoscopic electrosurgical unit and accessories.
- Section 882.4400 Radiofrequency lesion generator.
- Section 882.4725 Radiofrequency lesion probe.
 - Section 884.4150 Bipolar endoscopic coagulator-cutter and accessories.
- Section 884.4160 Unipolar endoscopic coagulator-cutter and accessories.
- Section 886.4100 Radiofrequency electrosurgical cautery apparatus.
- Section 886.4115 Thermal cautery unit.

122

118

- 123 In addition, please be aware that there may be supplemental guidance for electrosurgical
- devices for other specific indications (e.g., RF vessel sealers). In such instances,
- supplemental guidance may provide additional recommendations or supersede this guidance.
- We recommend that you search <u>FDA guidance databases</u>
- 127 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/d
- 128 <u>efault.htm</u>) for any device specific supplemental guidance or contact the General Surgery
- 129 Devices Branch 2 for more information.
- For a new device that combines an electrosurgical device with another device(s) (e.g.,
- mechanical massager or low level light source) into a single system, and is designed to
- operate simultaneously or in sequence to achieve a desired clinical effect in tissue, additional
- data requirements are usually necessary to demonstrate the new device is substantially
- equivalent to the predicate devices working independently. We recommend that you contact
- the Agency through the pre-submission process to obtain further guidance for data
- requirements. For information on the pre-submission process see FDA's guidance "Requests"
- for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings
- with Food and Drug Administration Staff"
- 139 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u
- 140 cm310375.htm).

141

III. Device Description

- We recommend that you identify your device by the applicable regulation number described
- in Section II and include the following information:

144 **A. Indications for Use**

- You should provide a clear statement of your device's Indications for Use. The
- Indications for Use as stated on the Indications for Use Statement page should be
- identical to that in the 510(k) Summary (if provided in lieu of a 510(k) Statement)
- and the device labeling. You should also state if the device is a prescription

Draft - Not for Implementation

(including home use) or Over-the-Counter (OTC) device, and indicate this accordingly on the Indications for Use Statement page.

B. Device Design

 You should provide a brief description of the device's operating principle(s) and mechanism of action for achieving the intended effects. If the device will be marketed with multiple components or accessories, and the components/accessories are part of the submission, you should provide a list of all components/accessories with accompanying model numbers and/or part numbers. For the purpose of this guidance, components/accessories of electrosurgical devices refer to the electrosurgical unit (ESU), active accessory, neutral electrode, and miscellaneous accessories. If there are components/accessories that have received prior 510(k) clearance or are exempted from the 510(k) requirement, please provide the 510(k) numbers or indicate their exemption status, respectively.

You should provide the following information regarding device design:

1. Device Components

We recommend you provide a brief description of all major components or accessories where applicable to your submission:

- Electrosurgical Unit (may be referred to as an ESU, generator, and/or control console) major functions, performance specifications, and physical specifications
- Active accessory (generally comprised of one or more active electrode(s), active connector or cables, and active handle or hand piece) design, physical specifications, and patient contacting materials
- Neutral electrodes (also commonly called dispersive electrodes, grounding pads, patient return electrodes, or passive/plate electrode) design, physical specifications, and patient contacting materials
- Miscellaneous accessories such as foot pedal, irrigation pumps, suction or smoke evacuation, etc.

2. Submission for Specific Component(s)/Accessories

If your submission is requesting clearance for a specific component or accessory but not the entire electrosurgical device, you should describe the component/accessory. You should discuss how you intend or expect this component/accessory to be used. For example, if the submission is for an active electrode and will only be marketed for use with your own legally marketed devices, you should provide performance testing (see Section XI Performance Data) to demonstrate compatibility with your own legally marketed devices. Also, you should address the likelihood that this active electrode could be used with other manufacturers' electrosurgical devices and, if so, identify the associated risk(s). Whether or not you intend to market the active electrode for use with another manufacturer's device, unless you have incorporated into your device design a way to prevent using your active electrode with other

Draft - Not for Implementation

manufacturers' devices, a risk assessment identifying potential hazards when using your active electrode with other manufacturers' devices should be provided. Based on your risk assessment, you may need to provide additional performance testing to demonstrate this component will be safe and effective when used with other manufacturers' devices.

3. Photograph and/or Drawing of the Device

We recommend you provide high level drawings, diagrams, and/or photographs of the device that can help explain the functions and features. We also recommend you provide a functional block diagram or connection diagram, including all components clearly labeled.

IV. Substantial Equivalence Comparison

We recommend that you compare your device with a legally marketed predicate device(s) that you believe is (are) substantially equivalent to your device with respect to indications for use and technology characteristics per 21 CFR 807.87(f). Side by side comparisons for each major component using a tabular format such as shown in Table 1 are desirable, whenever possible. For each identified difference, please provide further discussion of the difference compared to the predicate and why this difference will not significantly affect safety or effectiveness. You may need to provide performance data to support that even with significant differences the device is as safe and effective as the predicate.

Table 1. Example Comparison Table

	ple Comparison Table	
Description	Your Device	Predicate Device
Indications for Use		-
Prescription or OTC		
Electrosurgical Unit		
 Major functions (e.g. bipolar, 		
monopolar, temperature		
sensors, impedance monitor)		
 Performance Specifications 		
(e.g., output frequency,		
waveform, power output,		
voltage output, crest factor)		
 Physical Specifications 		
Active accessory		
 Monopolar or Bipolar 		
 Physical Dimensions and 		
Design (e.g. size, length,		
connector type)		
 Rated voltage 		
 Materials (e.g. electrode, 		
insulation, coating)		

Draft - Not for Implementation

Neutral electrodes	
 Conductive or Capacitive 	
 Physical Specifications 	
 Materials 	
Miscellaneous accessories	
 Functions 	
 Performance Specifications 	
 Physical Specification 	
Materials	

212213

214

215

216

217

218

219

220

221

222

223

When more than one predicate device is identified to establish substantial equivalence of your device, you should provide justification for the use of each predicate. You should address why the combination of features and/or functions into one device does not raise different types of safety and effectiveness questions for each predicate identified. An example of where multiple predicates could be used is if the device includes different technologies that can stand alone separately, but can also be used together for the intended use of cutting and coagulating tissue. If there is a predicate device for each of the technologies, then the combination of these technologies, assuming that the use of one of the functions does not interfere with the others, could be found substantially equivalent. In such an instance, you may need to provide performance data to support your justification.

V. Software

- Significance: Software in electrosurgical generators ensures that appropriate energy is
 delivered to the patient. Adequate software performance testing provides assurance that the
 device is operating within safe parameters.
- Recommendation: Please refer to the FDA guidance "Guidance for the Content of Premarket
 Submissions for Software Contained in Medical Devices"
- 229 (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceD
- ocuments/ucm089593.pdf) for a discussion of the software documentation that you should provide in your submission. The software guidance outlines the type of documentation to be
- provide in your submission. The software guidance outlines the type of documentation to be
- provided based on the "level of concern" associated with the device. FDA generally
- considers the software for electrosurgical device generators that are intended for general
- surgery indications to present a "moderate" level of concern. However, new or unusual
- indications, applications, or technological characteristics may result in a higher level of
- concern. If you believe that the software in your device presents either a "minor" or a
- 237 "major" level of concern as defined in the software guidance, you should provide a scientific
- justification that supports your rationale of the level of concern based on the possible
- consequences of software failure.
- We recommend that you provide a full description of the software/firmware supporting the
- operation of the subject device following the software guidance, commensurate with the
- 242 appropriate level of concern. This recommendation applies to original device/systems as well
- as to any software/firmware changes made to already-marketed devices. Changes to software

Draft - Not for Implementation

must be re-validated and re-verified in accordance with Design Controls, 21 CFR 244 245 820.30(g)(i), and documented in the Design History File 21 CFR 820.30(j). Some software 246 changes may warrant the submission of a new 510(k). 247 If the device includes off-the-shelf software, you should provide the additional information 248 as recommended in the FDA guidance titled "Guidance for Industry, FDA Reviewers and 249 Compliance on Off-the-Shelf Software Use in Medical Devices" 250 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u 251 cm073778.htm) 252 As appropriate, you should also provide information on the cybersecurity aspects of your 253 device, including, but not limited to, the following facets of information security with respect 254 to communications features of your device and associated software: confidentiality, 255 integrity, availability and accountability. 256 **Confidentiality** assures that no unauthorized users have access to the information. 257 258 **Integrity** is the assurance that the information is correct - that is, it has not been improperly 259 modified. 260 261 **Availability** suggests that the information will be available when needed. 262 Accountability is the application of identification and authentication to assure that the 263 264 prescribed access process is being done by an authorized user. The FDA guidance for industry, "Cybersecurity for Networked Medical Devices Containing 265 Off-The-Shelf (OTS) Software" 266 (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceD 267 268 ocuments/ucm077823.pdf) provides additional information regarding cybersecurity and 269 medical devices. 270 Overall, the documentation related to the software contained in the medical device should 271 provide sufficient evidence to describe the role of the software included in the device, and 272 performance testing to demonstrate that the software functions as designed. VI. **Biocompatibility** 273 274 Significance: Electrosurgical devices contain patient-contacting materials, which, when used 275 as intended, i.e., given the contact type and duration, may induce a harmful biological 276 response. 277 Recommendation: You should determine the biocompatibility of all patient-contacting 278 materials present in your device. For polymer materials, you should identify each material by 279 trade name and manufacturer. If your materials are identical in composition and processing 280 methods to materials used in a predicate device or another device with the same contact type 281 and duration (e.g., tissue contacting, less than 24 hours) for electrosurgical applications, you

may reference previous testing experience in lieu of new testing.

Draft - Not for Implementation

- 283 If biocompatibility testing is conducted in accordance with ISO 10993-1 Biological
- Evaluation of Medical Devices-Part 1: Evaluation and Testing, we recommend that you
- follow FDA's current guidance on this topic. See Blue Book Memorandum #G95-1 Use of
- 286 International Standard ISO-10993, "Biological Evaluation of Medical Devices Part 1:
- Evaluation and Testing," dated May 1, 1995. FDA is currently in the process of updating the
- 288 1995 guidance. For additional information on this topic see FDA's draft guidance "Use of
- 289 International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1:
- 290 Evaluation and Testing"
- 291 (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceD
- ocuments/UCM348890.pdf). FDA's draft guidance represents FDA's proposed approach on
- 293 this topic. When final, this document will supersede Blue Book Memorandum #G95-1.
- 294 Differences in formulation, processing, sterilization, or device surface properties (e.g., nano
- structuring) that could affect biocompatibility of the final product may warrant additional
- biocompatibility testing.

303

- 297 Most active electrodes should be considered external devices that contact tissue/bone/dentin
- for a limited contact duration (less than 24 hours). As a result, we recommend testing for:
- Cytotoxicity (See ISO 10993-5 Biological evaluation of medical devices Part 5:
 Tests for cytotoxicity);
- Intracutaneous reactivity (See ISO 10993-10 Biological evaluation of medical devices Part 10: Tests for irritation and delayed type sensitivity); and
 - Delayed type sensitivity (See ISO 10993-10 Biological evaluation of medical devices

 Part 10: Tests for irritation and delayed type sensitivity).
- Most dispersive electrodes should be considered external devices that contact only intact skin for a limited contact duration (less than 24 hours). As a result, we recommend testing for:
- Cytotoxicity (See ISO 10993-5 Biological evaluation of medical devices Part 5:
 Tests for cytotoxicity);
- Dermal irritation (See ISO 10993-10 Biological evaluation of medical devices Part
 Tests for irritation and delayed type sensitivity); and
- Delayed type sensitivity (See ISO 10993-10 Biological evaluation of medical devices
 Part 10: Tests for irritation and delayed type sensitivity).
- For biocompatibility testing conducted using extraction samples, we recommend that you:
- determine the appropriate amount of test material as outlined in ISO 10993-12
 (Biological Evaluation of Medical Devices Part 12: Sample Preparation and
 Reference Materials) or an equivalent method, using surface area to extractant
 volume ratios (mass to extractant volume ratios should only be used if surface area
- cannot be calculated);
- use both polar and nonpolar extractants;
- describe the condition of the extraction vehicle (e.g., color, presence of any particles);

Draft - Not for Implementation

321 • explain any changes in the post-extraction vehicle (compared to pre-extraction); and 322 • describe the details of storage conditions, if applicable. VII. Sterility 323 324 Significance: Electrosurgical devices for general surgery indications come in contact with 325 blood and body tissue and should be adequately sterilized to minimize infections and related 326 complications. 327 328 Recommendation: For electrosurgical devices labeled as sterile, we recommend that you 329 provide sterility information for the finished device. For information on sterility information 330 in 510(k) submissions for devices labeled as sterile see FDA's draft guidance "Submission 331 and Review of Sterility Information in Premarket Notification (510(k)) Submissions for 332 Devices Labeled as Sterile" 333 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u 334 cm109884.htm). FDA's draft guidance represents FDA's proposed approach on this topic. 335 You should sterilize the device to a sterility assurance level (SAL) of 1x10⁻⁶ using a 336 sterilization method and cycle that has been validated in accordance with the Quality System 337 Regulation (21 CFR Part 820). VIII. Reprocessing 338 Significance: Many of the patient contacting components of electrosurgical devices are 339 340 reused, and should be adequately cleaned, disinfected and sterilized between uses to 341 minimize infections and prevent device degradation. 342 343 Recommendation: Under the FDA labeling regulations (21 CFR Part 801), a device must 344 have adequate directions for use, which include instructions on preparing a device for use. 345 Instructions on how to reprocess a reusable device or a single-use device that is provided 346 non-sterile to the user are critical to ensure that a device is appropriately prepared for its 347 initial and / or subsequent uses. For information on the development and validation of 348 reprocessing instructions in your proposed device labeling, please see FDA's draft guidance 349 "Processing/Reprocessing Medical Devices in Health Care Settings: Validation Methods and

(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u

cm252999.htm). FDA's draft guidance represents FDA's proposed approach on this topic.

350

351

352

Labeling"

Draft - Not for Implementation

IX. Pyrogenicity

- 354 <u>Significance</u>: Pyrogenicity testing is used to help protect patients from the risk of febrile
- reaction due to gram-negative bacterial endotoxins and/or chemicals that can leach from a
- medical device (e.g., material-mediated pyrogens).

357

353

- 358 Recommendation: To address the risks associated with the presence of bacterial endotoxins,
- 359 electrosurgical devices labeled as "non-pyrogenic" should follow the recommendation in
- 360 Section VII Sterility. Proposed pyrogen limit specifications have been identified in FDA's
- 361 draft guidance "Submission and Review of Sterility Information in Premarket Notification
- 362 (510(k)) Submissions for Devices Labeled as Sterile"
- 363 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u
- 364 <u>cm109884.htm</u>). FDA's draft guidance represents FDA's proposed approach on this topic.
- To address the risks associated with material-mediated endotoxins, you should follow the
- 366 recommendations in Section VI Biocompatibility.
- For devices intended to be labeled as "non-pyrogenic," we recommend that both the bacterial
- and rabbit material-mediated pyrogen testing be conducted.

X. Shelf Life

- 370 <u>Significance</u>: Shelf life testing is conducted to support the proposed expiration date through
- evaluation of the package integrity for maintaining device sterility and/or evaluation of any
- changes to device performance or functionality.

373

369

- 374 Recommendation: With respect to package integrity for maintaining device sterility, you
- should provide a description of the packaging, including how it will maintain the device's
- 376 sterility, a description of the package integrity test methods, and a summary of the package
- integrity test results. FDA recommends that package integrity test methods include
- 378 simulated distribution and associated package integrity, as well as simulated (and/or real-
- 379 time) aging and associated seal strength testing, to validate package integrity and shelf life
- 380 claims. We recommend you follow the methods described in the FDA-recognized series of
- 381 consensus standards AAMI/ANSI/ISO 11607:2006 "Packaging for Terminally Sterilized
- 382 Medical Devices."

- With respect to evaluating the effects of aging on device performance or functionality, shelf
- 385 life studies should evaluate the critical physical and mechanical properties of the device that
- are required to ensure it will perform adequately and consistently during the entire proposed
- shelf life. To evaluate device functionality, we recommend that you assess each of the bench
- tests described in Section XI Performance Data and repeat all tests that evaluate design
- components or characteristics that are potentially affected by aging. For example, aging can
- affect the performance of most polymer materials used; therefore, tests that evaluate the
- integrity and performance of the insulation should be repeated after aging. For those bench
- tests that you do not repeat, you should provide a rationale explaining why the performance
- characteristics assessed by the tests are not expected to be affected by aging.

Draft - Not for Implementation

3	9	4
J		4

403

414

415 416

423

424

425

426

427

428

429

- 395 We recommend that you provide the protocol(s) used for your shelf life testing and the
- 396 conclusions drawn from your results. If you use devices subject to accelerated aging for shelf
- 397 life testing, we recommend that you specify the way in which the devices were aged. For
- 398 devices or components containing polymeric materials, you should plan to conduct testing on
- 399 real-time aged samples to confirm that the accelerated aging is reflective of real-time aging.
- 400 This testing should be conducted in parallel with 510(k) review and clearance, with results
- 401 documented to file in the design history file (i.e., the test reports do not need to be submitted
- 402 to FDA).

XI. **Performance Data**

- 404 We recommend that nonclinical testing be performed to demonstrate that each individual
- 405 component of the device, as well as the electrosurgical device with all the components
- 406 connected (system), meets all the design specification and performance requirements. In the
- 407 case where the 510(k) submission is for one or more components of the electrosurgical
- 408 device but not the entire electrosurgical device (e.g., electrosurgical generator only or active
- 409 electrodes only), nonclinical testing as a system may still be required using legally marketed
- 410 components that are most likely to be used with your device. Depending on the substantial
- 411 equivalence comparison to the predicate(s) above, nonclinical testing may be accomplished
- 412 with bench testing alone, or may require testing in an *in vivo* or *ex vivo* animal model. The
- 413 following are recommended nonclinical tests for each major component and for the system.

A. Electrosurgical Unit

For each mode, you should provide a graphical display of the output waveform at the rated load, identifying the associated mode, amplitude, frequency, duty cycle, load

used, and crest factor. 417

418 For each mode, you should provide a graph displaying the power output at maximum

and half of maximum intensity over the range of expected loads (e.g., 100Ω to 2000Ω 419

420 for monopolar). This information should be derived from experimental test data and 421

not theoretical values and should include a comparison of these curves to the

422 corresponding mode of the predicate device(s).

B. Active Component / Accessory

Mechanical testing of electrosurgical instruments is important to minimize the risks associated with mechanical failure and short circuiting. Although the methods will vary based on the device design, you should assess the potential for damage to the device both before use (e.g., drop tests of the instrument in its packaging) and during use (e.g., bending force). Different considerations will also be necessary for single use instruments versus reusable instruments. For reusable instruments, testing should demonstrate both adequate mechanical strength and electrical performance (e.g.,

430 431 insulation integrity) after multiple reuse and reprocessing cycles. For instruments

432 with actuating parts, we recommend simulated repeated use testing, grasping force,

Draft - Not for Implementation

433 and force to jaw failure. Testing of cutting performance of surgical scissors should 434 also be performed, where applicable. C. Neutral Electrodes 435 436 Neutral electrode thermal performance, contact impedance, and adhesion testing 437 should be performed in accordance with the currently FDA recognized version of IEC 438 60601-2-2 Clauses 201.15.101.5, 201.15.101.6 and 201.15.101.7. If alternative test 439 methods and test procedures are developed, a detailed description of the testing and 440 test results should be provided. In addition, you should provide a discussion 441 regarding why the testing and test results are comparable to the currently FDA 442 recognized version of the IEC 60601-2-2 standard. 443 As these standards may be periodically updated, please check the Recognized 444 Consensus Standards database 445 (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm) for the 446 most current information on which editions are recognized by FDA. 447 For reusable neutral electrodes, the above testing should be performed following 448 simulated reuse and reprocessing cycles according to the instructions for use. **D.** Miscellaneous Components / Accessories 449 450 When your electrosurgical device also includes accessories such as a foot pedal, irrigation pump, suction device, or smoke evacuation device, you should provide test 451 results to show that each of those accessories meets all of the design specification and 452 453 performance requirements. E. System Testing 454 In addition to the component testing, testing of the electrosurgical device with all the 455 components and accessories working together as a system may be necessary. The 456 457 following are examples of system testing that may be needed for electrosurgical 458 devices: 459 1. Thermal Effects on Tissue 460 For each mode and active electrode, you should provide a measurement (under 461 magnification) of the size (length, width and depth) of the thermal damage zone, 462 i.e., coagulation necrosis. This testing may be performed on ex vivo tissue and 463 should include at least three tissue types (e.g., liver, kidney, muscle tissues) to support a general soft tissue indication. At a minimum, each test should be 464 465 performed in triplicate at the minimum, default, and maximum intensity settings. 466 We recommend providing the results in a chart and/or graph that indicates the 467 width and depth of thermally damaged zone in relation to the tissue type, intensity 468 setting, and duration of activation. 469 For specific tissue type (e.g., lung or colorectal tissue) indications, additional 470 testing may be necessary in a chronic animal study. If you believe a chronic

animal study is necessary, we highly recommend that you contact the Agency

Draft - Not for Implementation

through the <u>Pre-Submission process</u> to obtain early feedback on your study design considerations.

2. Temperature Monitoring

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493 494

495

496 497

498

499

500

501

For electrosurgical devices that include temperature sensing, you should provide testing to demonstrate that this feature works as intended. Although the methods will vary based on the device design, your testing should demonstrate that the temperature sensing under simulated conditions meets your design specification and performance requirements.

3. Contact Quality Monitoring (CQM)

For electrosurgical generators and dispersive electrodes with contact quality monitoring capabilities, you should provide testing to demonstrate that this feature works as intended. Although the methods will vary based on the contact quality monitoring design, your testing should provide data on conditions where the contact quality monitoring is effective in order to write adequate instructions for use.

4. Capacitive Coupling

For laparoscopic/endoscopic electrosurgical electrodes and accessories, we recommend you test for active coupling resistance between the subject device and a conductive cannula/trocar device under simulated normal use conditions. Please consider the currently FDA recognized version of IEC 60601-2-18 Clause 201.11.101.2(c) for a recommended test set-up and pass/fail criteria.

You should provide complete test reports that include presentation of the test results, the test set-up and method, all test articles/components used, number of samples, predetermined acceptance criteria, study analysis, and a discussion of the results and conclusions drawn from the studies. You should describe the clinical relevance of the acceptance criteria for each test and explain why the test results demonstrate acceptable clinical performance of your device. Non-clinical test conditions should simulate the worst-case conditions that your device is likely to encounter during clinical use. Also, where applicable, the results should be compared to those of your predicate device(s).

XII. Electrical Safety and Electromagnetic Compatibility

- Significance: Electromagnetic compatibility (EMC) is the ability of a device to operate
- properly in its intended use environment without operating unexpectedly due to
- electromagnetic disturbances or introducing excessive electromagnetic disturbance into that
- 505 environment.
- Recommendation: All electrosurgical devices should undergo basic electrical, thermal, and
- electromagnetic performance testing to evaluate the potential for insufficient electrical safety
- and electromagnetic compatibility. We recommend that you conduct the required testing and
- comply with the labeling requirements outlined in the EN/IEC 60601 standards listed below.
- As these standards may be periodically updated, please check the Recognized Consensus
- 511 Standards database for the most current information on which editions are recognized by

Draft - Not for Implementation

- FDA. Given the potential variability in the test setup due to different designs and multiple components, sponsors should submit the complete test reports for these standards.
 - 60601-1: Medical electrical equipment Part 1: General requirements for basic safety and essential performance
 - 60601-1-2: Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance Collateral standard: Electromagnetic compatibility Requirements and tests
 - 60601-2-2: Medical electrical equipment Part 2-2: Particular requirements for the basic safety and essential performance of high frequency surgical equipment and high frequency surgical accessories
- Additionally, endoscopic/laparoscopic instruments should demonstrate compliance with 60601-2-18: Medical electrical equipment Part 2-18: Particular requirements for the basic safety and essential performance of endoscopic equipment.
- According to IEC 60601-2-2, high frequency surgical instruments are intentional emitters of
- 629 electromagnetic energy and, therefore, testing to IEC 60601-1-2 is only needed for power
- generators in the idle state (i.e., powered on, but energy not activated). However, even during
- idle testing, particular attention should be paid to the effects of connected accessories and
- instruments, such as cord length (for resonant frequency) and instruments that contain
- electronics. For instruments with different cord lengths, connection types, or electronic
- components it may not be appropriate to use a single "representative" instrument model for
- 535 testing purposes.
- If your submission is for a specific component of the electrosurgical device, you are still
- expected to evaluate your component while connected to other components of the
- electrosurgical device and consistent with how you intend or expect your component will be
- 539 used.

548

514

515

516517

518

519

520521

522

523 524

- 540 If your electrosurgical device uses wireless or RFID (radio frequency identification)
- technology, meeting the IEC 60601 standards is insufficient to demonstrate that your device
- will not be susceptible to electromagnetic interferences and that your wireless technology
- will perform reliably. Please review FDA's guidance "Radio-Frequency Wireless"
- 544 Technology in Medical Devices"
- 545 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/u
- 546 <u>cm077210.htm</u>) for a discussion on risks associated with wireless technology and
- suggestions regarding how to mitigate this risk.

XIII. Clinical Testing

- 549 Clinical data are generally not required to support 510(k) submissions for electrosurgical
- devices that are intended for general surgery indications. However, if your device indications
- for use or device technology and/or mechanism of action is significantly different when
- compared to the predicate device(s), and if nonclinical testing is insufficient to establish
- substantial equivalence, clinical testing may be necessary to establish substantial equivalence

Draft - Not for Implementation

- to a predicate device. For example, many electrosurgical devices for aesthetic use have
- utilized clinical data to demonstrate that the devices are as safe and effective as the predicate.
- If you believe that clinical data is necessary or if you are uncertain, we highly recommend
- that you contact the Agency through the Pre-Submission process to obtain early feedback on
- study design considerations.

XIV. Labeling

559

- The premarket notification must include labeling in sufficient detail to satisfy the
- requirements of 21 CFR 807.87(e). Proposed labels, labeling, and advertisements sufficient
- to describe the electrosurgical device, its intended use, and the directions for use must be
- provided with a specific intended use statement and any warnings, contraindications, or
- limitations clearly displayed as described in 21 CFR 807.87(e). Please consider the
- following suggestions for assistance in preparing labeling that satisfies the requirements of
- 566 21 CFR 807.87(e). The following suggestions are aimed at assisting you in preparing
- acceptable labeling.¹
- As a prescription device, under 21 CFR 801.109, the device is exempt from having adequate
- directions for lay use. Labeling must, however, include adequate information for practitioner
- use of the device, including indications, effects, routes, methods, frequency and duration of
- administration and any relevant hazards, contraindications, side effects and precautions. (21
- 572 CFR 801.109(d)).
- As stated above in Section XII Electrical Safety and Electromagnetic Compatibility, we
- recommend that all electrosurgical device submissions demonstrate compliance with the
- labeling requirements of the EN/IEC 60601 series of standards, including 60601-1, 60601-1-
- 2, 60601-2-2, and (when applicable) 60601-2-18. We also recommend that you include the
- information below in your labeling.²
- 578 Electrosurgical systems generally consist of several different interchangeable components
- used together to create the desired effect, including the ESU, active accessory, neutral
- electrodes, footswitches, etc. Some of the labeling recommendations below may apply to
- only a single component or to each component in a system. You should determine which
- labeling is appropriate, depending on the indications for use, the individual component and
- how the components may be packaged (together or separately). If your submission is for a
- specific component, your labeling should describe compatibility requirements and results
- from your risk assessment.

The list below is not intended to be exhaustive of all the labeling requirements under part

587 801.

-

¹ Although final labeling is not required for 510(k) clearance, final labeling must comply with the requirements of 21 CFR 801 before a medical device is introduced into interstate commerce. In addition, final labeling for prescription medical devices must comply with 21 CFR 801.109. Labeling recommendations in this guidance are consistent with the requirements of part 801.

² Note that some of the recommended labeling content is already included in the standards, but has been repeated for emphasis. Other recommended content has been modified from the standards.

Draft - Not for Implementation

A. Instructions for Use (User Manual)

1. Indications for Use

Your labeling should clearly state the indications for use of your device as specified in your Indications for Use Statement. This information should be prominently located in the beginning of your directions for use. If your device consists of multiple components with different indications, please specify this in your labeling. If your device is intended for use with another device, we recommend that you identify that device in your labeling.

2. Warnings

We recommend including the following warnings in the instructions for use. Sample language is provided in italics.

- a. DO NOT USE in patients who have electronic implants such as cardiac pacemakers without first consulting a qualified professional (e.g., cardiologist). A possible hazard exists because interference with the action of the electronic implant may occur, or the implant may be damaged.
- b. DO NOT USE in the presence of flammable anesthetics or oxidizing gases (such as nitrous oxide (N_2O) and oxygen) or in close proximity to volatile solvents (such as ether or alcohol), as explosion may occur.
- c. DO NOT place instruments near or in contact with flammable materials (such as gauze or surgical drapes). Instruments that are activated or hot from use may cause a fire.
- d. When not using instruments, place them in a clean, dry, highly visible area not in contact with the patient. Inadvertent contact with the patient may result in burns.
- e. DO NOT USE with hybrid trocar systems, i.e., a combination of metal and plastic. This may result in alternate site burns due to capacitive coupling. Use only all-metal or all-plastic trocar systems.
- f. INSPECT instruments and cables for damage prior to each use, especially the insulation of laparoscopic/endoscopic instruments. This may be done visually under magnification or with a high voltage insulation testing device. Insulation failures may result in burns or other injuries to the patient or operator.
- g. ASPIRATE fluid from the area before activating the instrument. Conductive fluids (e.g., blood or saline) in direct contact with or in close proximity to an active electrode may carry electrical current or heat away from target tissues, which may cause unintended burns to the patient.
- h. DO NOT activate the instrument when not in contact with target tissue, as this may cause injuries due to capacitive coupling.
- i. The surface of the active electrode may remain hot enough to cause burns after the RF current is deactivated.

Draft - Not for Implementation

628 629	j. Due to concerns about the carcinogenic and infectious potential of electrosurgical by-products (such as tissue smoke plume and aerosols),
630 631	protective eyewear, filtration masks, and effective smoke evacuation equipment should be used in both open and laparoscopic procedures.
632 633	k. Connect adaptors and accessories to the electrosurgical unit only when the unit is off. Failure to do so may result in an injury or electrical shock to the
634	patient or operating room personnel.
635	1. Prior to increasing the intensity, check the adherence of the neutral electrode
636	and its connections. Apparent low output or failure of the device to function
637 638	correctly at the normal operating settings may indicate faulty application of the neutral electrode or poor contact in its connections.
639 640	 m. If the device is argon enhanced, you should include warnings and recommendations regarding gas embolisms.
641	n. If the device uses a neutral electrode and does not have a CQM, you should
642	include a warning that loss of safe contact between the neutral electrode and
643	the patient will not result in an alarm.
644	o. If the device uses a neutral electrode and does have a CQM, you should
645	include a warning that loss of safe contact between the neutral electrode and
646 647	the patient will not result in an alarm unless a compatible monitoring neutral electrode is used.
648	3. Cautions
649	We recommend including the following cautions in the instructions for use. Sample
650	language is provided in italics.
651 652	a. The intensity should be set as low as is necessary to achieve the desired effect. [unless there is a risk associated with low settings, e.g., argon coagulation]
653	b. Keep the active electrodes clean. Build-up of eschar may reduce the
654	instrument's effectiveness. Do not activate the instrument while cleaning.
655	Injury to operating room personnel may result.
656	4. Operating Information
657	Operating instructions should contain detailed information such that the
658	practitioner can set up and use the device safely and for the purposes for which it
659	is intended. In addition, we recommend that you include instructions concerning
660	the proper selection and use of accessories in order to avoid incompatibility and
661	unsafe operation. In particular, you should include advice concerning the
662	compatibility between contact CQMs and neutral electrodes and direct the user to
663	verify that the generator's output voltage does not exceed the rated accessory
664	voltage.

For any accessories that may need to be replaced (e.g., disposable electrodes), you should also provide instructions in your labeling for obtaining replacements (e.g., model number and contact information).

Draft - Not for Implementation

B. Device Labels

In your submission, we recommend that you provide illustrations to show how each component of your device is labeled to demonstrate that all controls, switches and connections (including those for hand switched active electrodes and foot switches) are clearly, concisely and permanently labeled to identify their function and other important information (e.g., Type BF Applied Part). In the submission and the labeling, you should also describe the color of any controls or connections (e.g., blue "coag" button) so that the function of each is apparent. Your labels must include text adjacent to any symbols on your device (or a legend of symbols) that describes their meaning.

C. Package Labels

We recommend that you provide draft package labels, which should include the manufacturer, model number and important information about device reuse, sterility, shelf life, etc. You must include text adjacent to any symbols on your packaging (or a legend of symbols) that describes their meaning.

D. Labeling for Specific Components

1. Electrosurgical Unit

Your directions for use should include information on the output specifications of your device, so that the user can easily understand the energy that is being delivered. We recommend including the following information for each output mode of your device:

- a. Graphs or tables illustrating the actual power output (under a specified impedance) for each intensity setting.
- b. Graphs displaying the power output at maximum and half-of-maximum intensity over the range of expected impedances.
- c. The maximum output voltage and instructions regarding selecting accessories with appropriate voltage ratings.

2. Active components and accessory

Your directions for use should include information on the compatibility of your active electrodes with other components of the electrosurgical device. We recommend including the following information:

- a. The rated accessory voltage.
- b. The compatible generator model or adequate instructions and criteria for the user to identify an adequate generator.
- c. The limitations on generator output settings and duration of activation.
- d. A statement referring users to the generator and neutral electrode user manuals for additional instructions.

Contains Nonbinding Recommendations Draft - Not for Implementation

706 707 708		e. If the instrument is monopolar, clearly communicate to the user that the handpiece is a monopolar device, and that a dispersive electrode should be used with the generator to prevent burns/injury to the patient.
709 710 711 712		f. If the instrument is reusable, adequate instructions on the cleaning, inspection, and sterilization and how to track the number of uses. You should also include a warning that visual inspection alone may not be sufficient to ensure that the insulation is intact.
713 714 715 716 717 718		g. For ablation of tissue, the labeling should include a recommended ablation time per lesion size, a lesion size and shape range for which the device is effective, directions on how to perform multiple ablations on a single lesion including how you relocate the probe in a lesion, a time versus temperature versus lesion size created chart to inform users of the expected performance, and directions on how the user knows when an ablation is complete.
719 720 721 722	3.	Neutral Electrodes Your directions for use should include information on the compatibility of your neutral electrodes with other components of the electrosurgical device. We recommend including the following information:
723		a. The rated accessory voltage.
724		b. The surface area and size.
725 726		c. Adequate instructions for the user to identify a compatible contact quality monitor (CQM) or a warning that it is not compatible with CQMs.
727 728		d. The compatible generator model, or adequate instructions and criteria for the user to identify an adequate generator.
729		e. The limitations on generator output settings and duration of activation.
730		f. The appropriate patient population (e.g., size, weight).
731 732 733		g. Detailed instructions on how to apply the electrode to the patient, including recommendations for application site selection and preparation, warnings and precautions, and pre-application tests.
734 735 736 737 738	4.	Components and Accessories Your directions for use should include information on the compatibility for each of your accessories with the electrosurgical device. For some accessories, such as suction/irrigation pumps and smoke evacuation devices, a separate standalone instructions for use should be considered.

Draft - Not for Implementation

740 Appendix A: Glossary of Terms

774

775

776

741 The following terms are defined for the purpose of this guidance only and may or may not 742 correspond to their broader usage. active accessory – The component of the electrosurgical device used by the operator to 743 744 produce surgical effects at the intended site on the patient. Generally comprised an 745 active handle, the cord or cable, and the active electrode (monopolar or bipolar). 746 active electrode – The conductive portion of the electrosurgical device that delivers high 747 density electrical current to the patient at the surgical site. This may or may not be 748 removable from the active handle. 749 Argon beam coagulator – An electrosurgical device that combines the uses of argon gas with 750 RF current to form a plasma at the surgical site to effect hemostasis in bleeding tissue. 751 Besides Argon gas, other gas (e.g., nitrogen) has been used. 752 bipolar – An electrosurgical device in which the current flows between two active electrodes 753 placed in close proximity. 754 coagulation – The change of a liquid, especially blood, to a solid. This is considered separate 755 from coagulation necrosis. 756 coagulation necrosis – Necrosis in which the affected cells or tissue are converted into a dry, opaque, fairly homogenous eosinophilic mass as a result of the coagulation of protein. 757 contact quality monitor (CQM) – A component of a monopolar electrosurgical system that 758 759 monitors the contact between the neutral electrode and the patient. The CQM produces 760 an alarm if the contact becomes insufficient and the patient is at risk for burns. 761 continuity monitor – A component of a monopolar electrosurgical system that monitors the 762 connection between the neutral electrode and the generator. The continuity monitor 763 produces an alarm if the connection is lost, but it cannot detect if there may be a high 764 current density through the neutral electrode. 765 dispersive electrode – An electrode connected to the patient, in an anatomical location away 766 from the surgical site, to provide a return path for the high frequency current. The 767 dispersive electrode has a large area relative to the active electrode in order to provide a 768 low current density. Also known as: patient plate, ground pad, return electrode, neutral 769 electrode, inactive electrode, passive electrode, indifferent electrode, etc. 770 electrocautery – The use of electric current to heat an instrument, which is applied to tissue 771 to create an effect. The current passes through the instrument only and not through the 772 patient's tissue. 773 NOTE: The term electrocautery is often used incorrectly to refer to electrosurgical

devices. To prevent confusion, FDA recommends that you avoid misuse of this term.

electrosurgical device – A device that passes high-frequency electrical current through soft

tissues for the purpose of removing tissue or controlling bleeding.

Contains Nonbinding Recommendations Draft - Not for Implementation

777 778 779	ESU – acronym for electrosurgical unit – This term may be used to refer to the generator only or to the entire system (generator plus electrodes and accessories). It may also be used as a descriptive term for an electrode or accessory (e.g., "ESU handpiece").
780 781 782	generator – The component of the electrosurgical system that produces the high frequency current waveform that is delivered to tissues via the connecting cable(s), instrument(s), and electrode(s).
783 784 785	hyfrecator – A type of monopolar electrosurgical device in which the current flows from a single active electrode at the surgical site and returns to earth (ground) through the patient's own body capacitance.
786 787	instrument – The component of the electrosurgical system that is manipulated by the operator and applied to the surgical site, generally consisting of the handle and active electrode.
788 789 790	monopolar – An electrosurgical technique in which the current flows from a single active electrode at the surgical site, through the patient, to a relatively distant neutral electrode.
791 792 793 794	radiofrequency (RF) – Generally refers to frequencies ranging from 100 kHz to 5 MHz. This is intended to exclude other frequencies (e.g., microwave ablation devices) that may technically fall within the radiofrequency portion of the electromagnetic spectrum but operate in a fundamentally different manner.
795 796 797	vessel sealer—An electrosurgical device intended to seal isolated blood and lymphatic vessels for hemostasis, as an alternative to ties. Usually bipolar.